Get the Stockscreener App
7.16
1.42%
0.10
After Hours:
7.16
Neuraxis Inc stock is traded at $7.16, with a volume of 63,968.
It is up +1.42% in the last 24 hours and up +4.68% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$7.06
Open:
$7.02
24h Volume:
63,968
Relative Volume:
0.43
Market Cap:
$88.67M
Revenue:
$4.28M
Net Income/Loss:
$-7.28M
P/E Ratio:
-8.7896
EPS:
-0.8146
Net Cash Flow:
$-6.17M
1W Performance:
+0.28%
1M Performance:
+4.68%
6M Performance:
+60.54%
1Y Performance:
+177.52%
1-Day Range:
$7.02
$7.47
1-Week Range:
$6.77
$7.47
52-Week Range:
$2.1963
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
7.16 | 90.53M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc Stock (NRXS) Latest News
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Growth Benchmark - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Index - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Index - marketscreener.com
Price to sales forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Price to sales forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Enterprise value to EBIT forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Enterprise value to EBIT forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Price to book forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Enterprise value to revenue forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Price to earnings forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Enterprise value to EBITDA forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
NeurAxis, Inc. Actuals & Estimates (AMEX:NRXS) - TradingView
NRXS Forecast — Price Target — Prediction for 2027 - TradingView
Neuraxis Inc (NRXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuraxis Inc (NRXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuraxis Inc (NRXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuraxis Inc (NRXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuraxis Inc (NRXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuraxis Inc (NRXS) Institutional Confidence - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuraxis Inc (NRXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuraxis Inc (NRXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NeurAxis Stockholders Approve Directors and Equity Compensation Plans - The Globe and Mail
Neuraxis elects board members and approves plan amendments at annual meeting - Investing.com
NRXS Q1 2026 Earnings: Smaller-than-Expected Loss Bolsters Investor SentimentShare Repurchase Impact - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates Amid Ongoing Development FocusGuidance Accuracy Score - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates but Stock Declines on Broader ConcernsBalance Sheet Strength - newsline.com
NRXS Q1 2026 Earnings: EPS Beat Surprises as Pre-Revenue Biotech Tightens LossesEstimate Revision Count - The Legal Advocate
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionForward EPS Estimate - thelegaladvocate.com
Neuraxis Inc. (NRXS) Slides 2.15% as Key Support Level TestedPCR Divergence - The Legal Advocate
NRXS: Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets - TradingView
NRXS Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceRevenue Warning Signal - The Legal Advocate
NRXSNeuraxis Inc Stock Price and Quote - Finviz
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Surpasses Estimates Amid Operational ProgressGAAP Earnings Report - The Legal Advocate
Neuraxis Inc. (NRXS) Holds Near Support After Marginal DeclineMA Cross Alert - Newser
Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Slips on Pre‑Revenue Concerns - Newser
NeurAxis Earnings Call Highlights Growth and Hurdles - The Globe and Mail
NeurAxis (NRXS) Gains on Reimbursement Updates and Guideline MomentumShare Dilution Risk - The Legal Advocate
Minot Light Capital Fund Drops 2.7 Percent Amid Sector Rotation - HarianBasis.co
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum - Insider Monkey
Neuraxis (NRXS) Stock Analysis: -5.84% Loss — Key Levels 2026-05-18Stock Idea Hub - Newser
NeurAxis slides 21%, raises $5M via stock - MSN
The surprise hidden in Neuraxis NRXS last earnings report Q4 2025 Earnings Beat EstimatesCrowd Verified Signals - Newser
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y - Yahoo Finance
NeurAxis revenues up 80% to USD 1.6M in Q1 2026 - Medical Buyer
Craig-Hallum Sticks to Its Buy Rating for NeurAxis, Inc. (NRXS) - The Globe and Mail
TradingKey - TradingKey
NeurAxis signals burn rate of $1M or less for rest of 2026 while targeting ~ $15M revenue for cash flow breakeven - MSN
Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges - Investing.com Canada
Earnings call transcript: Neuraxis Q1 2026 sees record revenue growth - Investing.com
Neuraxis Inc Stock (NRXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuraxis Inc Stock (NRXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carrico Thomas Joeseph | CRO, CCO, CPO |
Apr 01 '26 |
Buy |
1.96 |
667 |
1,307 |
331,903 |
| Carrico Brian Allen | Chief Executive Officer |
Apr 01 '26 |
Buy |
1.96 |
8,060 |
15,798 |
348,178 |
| Hannasch Brian | 10% Owner |
Feb 12 '26 |
Buy |
4.92 |
40,000 |
196,800 |
1,211,522 |
| Hannasch Brian | 10% Owner |
Feb 11 '26 |
Buy |
4.65 |
40,000 |
186,000 |
1,171,522 |
| Aharon Gil | Director |
Dec 23 '25 |
Buy |
3.52 |
286,138 |
1,007,206 |
286,138 |
0.05%
0.74%
Cap:
|
Volume (24h):